Meeting
2019 ASCO Annual Meeting
Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies.
Authors
Madison Conces
Cleveland Clinic, Cleveland, OH
Madison Conces , Ying Ni , Peter Bazeley , Bhumika Patel , Pauline Funchain , Hetty E Carraway
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Cancer Prevention, Hereditary Genetics, and Epidemiology
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Genetics
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1507)
DOI
10.1200/JCO.2019.37.15_suppl.1507
Abstract #
1507
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.
First Author: Catherine Callaghan Coombs
Poster
2021 ASCO Annual Meeting
Prevalence of inferred clonal hematopoiesis (CH) detected on comprehensive genomic profiling (CGP) of solid tumor tissue or circulating tumor DNA (ctDNA).
First Author: Emmanuel S. Antonarakis
Poster
2023 ASCO Annual Meeting
Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers.
First Author: Catherine Handy Marshall
Poster
2023 ASCO Annual Meeting
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.
First Author: Maha AT Elsebaie